

**Anxiety during a 12-month follow-up
in patients with obesity and MDD
(comparison between propensity-score matched cohorts)**

Population	Semaglutide cohort	Non-GLP-1RAs anti-obesity medications cohort	HR (95% CI)
Overall (n = 6,712/cohort)	44.1% (2,962)	48.3% (3,240)	0.89 (0.85–0.94)
Women (n = 4,962/cohort)	44.7% (2,215)	48.2% (2,409)	0.91 (0.86–0.96)
Men (n = 1,348/cohort)	40.5% (546)	45.7% (616)	0.84 (0.75–0.94)
age <= 45 years (n = 2,084/cohort)	51.1% (1,064)	54.8% (1,142)	0.90 (0.83–0.98)
age 46–64 years (n = 3,220/cohort)	43.4% (1,397)	45.7% (1,471)	0.93 (0.86–1.00)
age >=65 years (n = 1,404/cohort)	36.3% (510)	40.5% (569)	0.88 (0.78–0.99)
Black (n = 763/cohort)	39.1% (298)	39.5% (301)	0.99 (0.85–1.17)
White (n = 4,857/cohort)	44.6% (2,168)	48.6% (2,361)	0.89 (0.84–0.95)
No T2DM (n = 3,369/cohort)	46.3% (1,560)	50.9% (1,714)	0.89 (0.83–0.96)
T2DM (n = 3,271/cohort)	42.6% (1,395)	44.9% (1,469)	0.92 (0.86–0.99)

